id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S3510 R6883 |
Spielmann (Control mainly exposed other treatments, sick), 2017 | All birth defects | 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
1.14 [0.65;2.00] C excluded (control group) |
24/328 28/431 | 52 | 328 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S3509 R6859 |
Spielmann (Control unexposed, disease free), 2017 | All birth defects | 1st trimester | prospective cohort | unexposed, disease free | Adjustment: No | 1.20 [0.75;1.91] C | 24/328 95/1,538 | 119 | 328 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S3492 R6763 |
Nezvalová-Henriksen (Control unexposed, disease free), 2013 | Congenital malformations (any) | 1st trimester | population based cohort retrospective | unexposed, disease free excluded | Adjustment: Yes |
1.13 [0.89;1.44] excluded (control group) |
72/1,210 9,136/178,565 | 9,208 | 1,210 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S851 R6745 |
Nezvalová-Henriksen (Control unexposed, sick), 2013 | Congenital malformations (any) | 1st trimester | population based cohort retrospective | unexposed, sick | Adjustment: No | 0.97 [0.69;1.37] C | 72/1,210 67/1,095 | 139 | 1,210 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S850 R11398 |
Bérard, 2012 | Major congenital malformations | during pregnancy (anytime or not specified) excluded | nested case control | unexposed, disease free | Adjustment: Yes |
1.49 [0.89;2.52] excluded (exposition period) |
18/139 4,698/59,568 | 4,716 | 139 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S3494 R6812 |
Källén (control exposed to ergots), 2011 | Any congenital malformations | 1st trimester | population based cohort propective | exposed to other treatment, sick excluded | Adjustment: No |
1.15 [0.72;1.85] C excluded (control group) |
127/2,777 21/527 | 148 | 2,777 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S849 R6557 |
Källén (control unexposed, disease free), 2011 | Any congenital malformations | 1st trimester | population based cohort propective | unexposed, disease free | Adjustment: Yes | 0.97 [0.81;1.16] | 127/2,777 56,759/1,229,901 | 56,886 | 2,777 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S3595 R11396 |
Shuhaiber - Sumatriptan (Control exposed to other treatments), 1998 | Major congenital malformations | at least 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
1.10 [0.07;17.86] C excluded (control group) |
1/82 1/90 | 2 | 82 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S3596 R11397 |
Shuhaiber - Sumatriptan (Control unexposed, disease free), 1998 | Major congenital malformations | at least 1st trimester | prospective cohort | unexposed, disease free | Adjustment: No | 1.11 [0.07;18.06] C | 1/82 1/91 | 2 | 82 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 4 studies | 0.99 [0.85;1.15] | 57,146 | 4,397 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Control unexposed, disease free; 2: Control unexposed, sick; 3: control unexposed, disease free; 4: Control unexposed, disease free;
Asymetry test p-value = NaN (by Egger's regression)
not enought points
excluded 3595, 3494, 3492, 3510